Digital Asset Treasury Companies Now Holding $135,000,000,000 in Total Assets, According to VanEck
Asset manager VanEck says companies holding digital asset treasuries (DATs) have now accumulated over $135 billion worth of cryptocurrencies.
In a new report, VanEck notes that September saw a large inflow of capital into DATs, with Strategy (MSTR) dominating about 53% of the total assets under management.
Sasys the firm,
“Thematically, September 2025 was characterized by the continued growth of digital asset treasuries (DATs), which swelled to hold around ~$135B in assets (~53% in MSTR). DATs are entities that utilize financialization to increase common share exposure to digital assets. Some DAT EVs currently trade at mNAV premiums to the value of their digital asset treasury holdings. We believe this is partly explained by the market assigning a premium to entities that have a credible long-term ability to increase per-share digital asset exposure. To purchase more digital assets, companies often sell securities whose valuations are linked to the underlying volatility of the company’s stock.
In order to ‘reap’ the benefits of the volatility of their common shares (and the underlying digital assets), these entities must price the volatility they are selling well below the implied volatility of options. This allows sophisticated market participants to buy relatively cheap volatility (through common shares, convertible debt, or warrant sales) and hedge against relatively expensive options portfolios. These savvy traders then expect the volatility of the two positions to converge over time, enabling a profit on the trade.”
Although Strategy was the first company to adopt a digital asset treasury (DAT) strategy in 2020, and by September 2025, more than 200 companies worldwide have now followed suit.
Generated Image: DALLE3
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP News Today: SEC Approves Altcoin ETFs, Boosting Institutional Investment in Cryptocurrency
- SEC approves multiple XRP/DOGE ETFs from 21Shares, Franklin Templeton, and Grayscale, signaling growing institutional acceptance of altcoins. - 21Shares' TOXR ETF gains automatic approval via CME CF XRP-Dollar tracking, with Coinbase and BNY Mellon handling custody/admin functions. - Franklin Templeton's XRP Trust removes restrictive clauses to accelerate listing, offering regulated exposure without custody risks from ledger forks. - Grayscale expands crypto offerings with XRP/DOGE ETFs on NYSE, joining
Germany's Solar Turning Point: Spotlight on Legislation, Infrastructure, and Ideological Differences
- Germany's SolarPlus Forum 2025 emphasized legislative clarity, funding innovation, and cross-sector collaboration to accelerate solar adoption amid evolving energy policies. - Outdated regulations and permitting hurdles were highlighted as barriers, with calls to align Bundestag reforms with market demands like gas surcharge removal by 2026. - Cement industry growth (5.7% CAGR) and green innovations support infrastructure needs, though energy cost volatility and compliance challenges persist. - Internati
Polkadot Latest Updates: ECB Raises Concerns: Cryptocurrency and Stock Market Downturns Resemble Dot-Com Bubble Threats
- ECB warns U.S. equity/crypto corrections threaten stability, urging central banks to retain rate-cut flexibility amid market volatility. - JPMorgan links crypto ETF outflows to retail investor behavior, noting $4B November sales contrast with $96B equity ETF inflows. - U.S. Treasury downplays recession risks, citing 2026 growth optimism despite shutdown impacts and services-driven inflation. - MSCI highlights tech valuation risks akin to dot-com era, while DeFi faces $12B liquidity crisis with 95% capita
Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats
- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution
Trending news
MoreCrypto prices
More
